News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
February 2021
-
Reimagining Healthcare in Challenging Times: Novartis in Society US Report for 2020
Novartis is striving every day to help patients, strengthen communities, drive sustainability and build a more equitable healthcare system for all.
-
Telemedicine is helping patients in underserved communities access quality healthcare
The Novartis US Foundation partners with local groups to improve healthcare in underserved communities, including by expanding use of telemedicine.
January 2021
-
Media ReleaseNovartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic idiopathic urticaria (CIU)Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic idiopathic urticaria (CIU) in patients with an inadequate response to H1 anthistamines1 Currently…
-
StatementNovartis US response to COVID-19
December 2020
-
Working Together at Novartis to Fight COVID-19 and Help People in Need
Novartis is fighting COVID-19 broadly, from committing R&D resources to better understand and treat the disease to reaching out to individuals and communities in need.
-
Media ReleaseNovartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
-
Media ReleaseNovartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEFThe Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval…
-
Media ReleaseNovartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
-
Media ReleaseNovartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancerMONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1 Kisqali plus endocrine therapy had a median OS of nearly five years (58.7…
-
Media ReleaseNovartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
-
Media ReleaseNovartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trialAt 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase…
-
Media ReleaseNovartis and Amgen partner with Karamo Brown to support and empower people living with migraine
Pagination
- ‹ Previous page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- …
- 56
- › Next page